M195是早期髓系细胞表面分化抗原CD33免疫小鼠产生的一种单克隆抗体,它能以细胞表面的CD33抗原为靶标,并与之特异性结合而杀伤细胞。HuM195的产生削弱了抗体的免疫原性,提高了与靶细胞的亲和力,当与放射性核素或免疫毒素结合时形成免疫偶联物,组成抗肿瘤MoAb药物,可明显提高杀伤白血病细胞的能力,初步临床应用前景看好。 M195 is a monoclonal antibody produced by the early myeloid cell surface differentiation antigen CD33-immunized mice, which targets CD33 antigens on cell surface and specifically binds to kill cells. The production of HuM195 weakens the immunogenicity of the antibody and enhances its affinity with target cells. When combined with radionuclide or immunotoxin, it forms an immunoconjugate and constitutes an anti-tumor MoAb drug, which can obviously improve the ability of killing leukemia cells, Preliminary clinical application is promising.